Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI 46 EBIT per Share is kr0.02 as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.56 (Significantly Undervalued). Among 812 Drug Manufacturers companies, ODI Pharma AB ranks better than 61.21% on this metric.
ODI Pharma AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ODI Pharma AB's EBIT per Share or its related term are showing as below:
XSAT:ODI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -29.6 Med: -7.5 Max: 14.9
Current: 14.9
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of ODI Pharma AB was 14.90% per year. The lowest was -29.60% per year. And the median was -7.50% per year.
XSAT:ODI's 3-Year EBIT Growth Rate is ranked better than 61.21% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.55
vs XSAT:ODI: 14.90
ODI Pharma AB's EBIT for the
three
months ended in Mar. 2026 was kr0.31 Mil.
ODI Pharma AB (XSAT:ODI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ODI Pharma AB EBIT per Share Related Terms
ODI Pharma AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a EBIT per Share of kr0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ODI Pharma AB and its competitors. According to the industry distribution chart, ODI Pharma AB ranks #315 out of 812 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is ODI Pharma AB's EBIT per Share too high?
ODI Pharma AB's current EBIT per Share is kr0.02. Based on the distribution chart, ODI Pharma AB ranks #315 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #315 out of 812 companies for EBIT per Share. This puts ODI Pharma AB in the upper half of its industry. The industry median EBIT per Share is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current EBIT per Share is kr0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.56, compared to a current price of kr2.54 — trading 73.4% below its estimated fair value. The current EBIT per Share is kr0.02. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current EBIT per Share is kr0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.54 is trading 73.4% below its estimated GF Value™ of kr9.56.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
EBIT per Share: kr0.02
GF Value™: kr9.56 vs. price of kr2.54 (73.4% below fair value)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
